Binding of pimecrolimus and tacrolimus to skin and plasma proteins: Implications for systemic exposure after topical application

Drug Metabolism and Disposition

Volumn 36, Issue 9, 2008, Pages 1812-1818

  Weiss, H Markus ^a   Fresneau, Marcel ^a   Moenius, Thomas ^a   Stuetz, Anton ^b   Billich, Andreas ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Novartis Institutes for BioMedical Research Vienna   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CALCINEURIN INHIBITOR; CYTOPLASM PROTEIN; LIPOPROTEIN; MACROPHILIN 12; PIMECROLIMUS; SILICON; TACROLIMUS; UNCLASSIFIED DRUG;

ARTICLE; ATOPIC DERMATITIS; BINDING AFFINITY; DRUG DISPOSITION; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; LIPOPHILICITY; PRIORITY JOURNAL; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; BLOOD PROTEINS; CHROMATOGRAPHY, LIQUID; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PROTEIN BINDING; SKIN; TACROLIMUS; TANDEM MASS SPECTROMETRY;

EID: 50049084618     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.021915     Document Type: Article

References (26)

1. Allen A, Siegfried E, Siverman R, Williams ML, Elias PM, Szabo SK, and Korman NJ (2001) Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 137:747-750.
2. Bavandi A, Fahrngruber H, Aschauer H, Hartmann B, Meingassner JG, and Kalthoff FS (2006) Pimecrolimus and tacrolimus differ in their inhibition of lymphocyte activation during the sensitization phase of contact hypersensitivity. J Dermatol Sci 43:117-126.
3. Berger G and Girault G (2003) Macromolecule-ligand binding studied by the Hummel and Dreyer method: current state of the methodology. J Chromatogr B Analyt Technol Biomed Life Sci 797:51-61.
4. Billich A, Aschauer H, Aszódi A, and Stuetz A (2004) Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm 269:29-35.
5. Draelos Z, Nayak A, Pariser D, Shupack JL, Chon K, Abrams B, and Paul CF (2005) Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. J Am Acad Dermatol 53:602-609.
6. Galat A (2003) Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity - targets-functions. Curr Top Med Chem 3:1315-1347.
7. Ginsberg HN (1998) Lipoprotein physiology. Endocrinol Metab Clin North Am 27:503-519.
8. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, Schuler W, Schulz M, Werner FJ, Winiski A, et al. (1999) A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 141:264-273.
9. Grassberger M, Steinhoff M, Schneider D, and Luger TA (2004) Pimecrolimus - an antiinflammatory drug targeting the skin. Exp Dermatol 13:721-730.
10. Hummel JP and Dreyer WJ (1962) Measurement of protein-binding phenomena by gel filtration. Biochim Biophys Acta 63:530-532.
11. Kalthoff FS, Winiski A, Fichtinger P, Schwendinger B, Wang S, Weishaeupl C, and Stuetz A (2007) Differential inhibition of primary versus preactivated T cells by pimecrolimus but not by tacrolimus in vitro. Int Arch Allergy Immunol 142:255-264.
12. Kissinger CR, Parge HE, Knighton DR, Lewis CT, Pelletier LA, Tempczyk A, Kalish VJ, Tucker KD, Showalter RE, and Moomaw EW (1995) Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex. Nature 378:641-644.
13. Meingassner JG, Fahrngruber H, and Bavandi A (2003) Pimecrolimus inhibits the elicitation phase but does not suppress the sensitization phase in murine contact hypersensitivity, in contrast to tacrolimus and cyclosporin A. J Invest Dermatol 121:77-80.
14. Meingassner JG, Aschauer H, Stuetz A, and Billich A (2005) Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroid- pretreated skin. Exp Dermatol 14:752-757.
15. Nagase K, Iwasaki K, Nozaki K, and Noda K (1994) Distribution and protein binding of FK506, a potent immunosuppressive macrolide lactone, in human blood and its uptake by erythrocytes. J Pharm Pharmacol 46:113-117.
16. Oji V, Beljan G, Beier K, Traupe H, and Luger TA (2005) Topical pimecrolimus: a novel therapeutic option for Netherton syndrome. Br J Dermatol 153:1067-1068.
17. Olson RE (1998) Discovery of the lipoproteins, their role in fat transport and their significance as risk factors. J Nutr 128(Suppl 2):439S-443S.
18. Piekoszewski W and Jusko WJ (1993) Plasma protein binding of tacrolimus in humans. J Pharm Sci 82:340-341.
19. Schmook FP, Meingassner JG, and Billich A (2001) Comparison of human skin or epidermis models with human and animal skin in in-vitro percutaneous absorption. Int J Pharm 215:51-56.
20. Stuetz A, Baumann K, Grassberger M, Wolff K, and Meingasser JG (2006) Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus. Int Arch Allergy Immunol, 141:199-212.
21. Stuetz A, Grassberger M, and Meingassner JG (2001) Pimecrolimus (Elidel, SDZ ASM 981) - preclinical pharmacological profile and skin selectivity. Semin Cutan Med Surg 20:233-241.
22. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, McMichael J, Lever J, Burckart G, and Starzl T (1995) Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 29:404-430.
23. Weiwad M, Edlich F, Kilka S, Erdmann F, Jarczowski F, Dorn M, Moutty MC, and Fischer G (2006) Comparative analysis of calcineurin inhibition by complexes of immunosuppressive drugs with human FK506 binding proteins. Biochemistry 45:15776-15784.
24. Zahir H, McCaughan G, Gleeson M, Nand RA, and McLachlan AJ (2004) Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br J Clin Pharmacol 57:298-309.
25. Zahir H, Nand RA, Brown KF, Tattam BN, and McLachlan AJ (2001) Validation of methods to study the distribution and protein binding of tacrolimus in human blood. J Pharmacol Toxicol Methods 46:27-35.
26. Zollinger M, Waldmeier F, Hartmann S, Zenke G, Zimmerlin AG, Glaenzel U, Baldeck JP, Schweitzer A, Berthier S, Moenius T, et al. (2006) Pimecrolimus: absorption, distribution, metabolism, and excretion in healthy volunteers after a single oral dose and supplementary investigations in vitro. Drug Metab Dispos 34:765-774.